{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:31Z","timestamp":1791868951938,"version":"4.3.4"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,12,19]]},"DOI":"10.1001\/jama.2023.21106","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:01:17Z","timestamp":1703001677000},"page":"2304","source":"Crossref","is-referenced-by-count":11,"title":["Use of Donanemab in Early Symptomatic Alzheimer Disease"],"prefix":"10.1001","volume":"330","author":[{"given":"Nunzio","family":"Pomara","sequence":"first","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, NYU Grossman School of Medicine, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Pietro","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"Research and Development, Chiesi Farmaceutici, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"jle230128r1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"jle230128r2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2023.11703","article-title":"Amyloid-targeting monoclonal antibodies for Alzheimer disease.","volume":"330","author":"Rabinovici","year":"2023","journal-title":"JAMA"},{"issue":"16","key":"jle230128r3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis.","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"issue":"7806","key":"jle230128r4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"issue":"1","key":"jle230128r5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13195-023-01199-5","article-title":"Changes in CSF sPDGFR\u00df level and their association with blood-brain barrier breakdown in Alzheimer\u2019s disease with or without small cerebrovascular lesions.","volume":"15","author":"Lv","year":"2023","journal-title":"Alzheimers Res Ther"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2812915\/jama_pomara_2023_le_230128_1702929679.02577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:01:19Z","timestamp":1703001679000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2812915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":5,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,19]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.21106","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}